Affordable Access

deepdyve-link
Publisher Website

Mast cells and mastocytosis.

Authors
  • Metcalfe, Dean D
Type
Published Article
Journal
Blood
Publisher
American Society of Hematology
Publication Date
Aug 15, 2008
Volume
112
Issue
4
Pages
946–956
Identifiers
DOI: 10.1182/blood-2007-11-078097
PMID: 18684881
Source
Medline
License
Unknown

Abstract

Mast cells have been recognized for well over 100 years. With time, human mast cells have been documented to originate from CD34+ cells, and have been implicated in host responses in both innate and acquired immunity. In clinical immunology, they are recognized for their central role in IgE-mediated degranulation and allergic inflammation by virtue of their expression of the high-affinity receptor for IgE and release of potent proinflammatory mediators. In hematology, the clinical disease of mastocytosis is characterized by a pathologic increase of mast cells in tissues, often associated with mutations in KIT, the receptor for stem cell factor. More recently, and with increased understanding of how human mast cells are activated through receptors including the high-affinity receptor for IgE and KIT, specific tyrosine kinase inhibitors have been identified with the potential to interrupt signaling pathways and thus limit the proliferation of mast cells as well as their activation through immunoglobulin receptors.

Report this publication

Statistics

Seen <100 times